NCT00715403 - A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2009

Conditions

Neoplasms

Interventions

DRUG

BIBF 1120

Trial Locations (11)

1199.16.3306A Boehringer Ingelheim Investigational Site, Bordeaux

1199.16.3311A Boehringer Ingelheim Investigational Site, Clichy

1199.16.3311B Boehringer Ingelheim Investigational Site, Clichy

1199.16.3302A Boehringer Ingelheim Investigational Site, Paris

1199.16.3312A Boehringer Ingelheim Investigational Site, Paris

1199.16.3313A Boehringer Ingelheim Investigational Site, Paris

1199.16.3313E Boehringer Ingelheim Investigational Site, Paris

1199.16.49001 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau

1199.16.49004 Boehringer Ingelheim Investigational Site, Großhansdorf

1199.16.49008 Boehringer Ingelheim Investigational Site, Tübingen

1199.16.49005 Boehringer Ingelheim Investigational Site, Wiesbaden